Compare AMTX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | ATOS |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 83.3M |
| IPO Year | N/A | 2012 |
| Metric | AMTX | ATOS |
|---|---|---|
| Price | $1.64 | $5.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $17.00 | ★ $31.67 |
| AVG Volume (30 Days) | ★ 1.1M | 210.2K |
| Earning Date | 03-13-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,323,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $139.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $4.91 |
| 52 Week High | $3.66 | $19.35 |
| Indicator | AMTX | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 90.32 |
| Support Level | $1.55 | $4.91 |
| Resistance Level | $1.83 | $7.56 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | 0.01 | 0.58 |
| Stochastic Oscillator | 38.89 | 68.04 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.